Matthias Kleinz, DVM, PhD

Matthias Kleinz, DVM, PhD, is Executive Vice President, Translational Sciences at UPMC Enterprises. Matthias joined UPMC Enterprises in July 2017 to help the ITTC invest and commercialize innovative translational science by defining the true potential of new life science technologies, exploring optimal business models and strategies, and helping to form companies with a clear path to success. Matthias sits on the board of UPMC Enterprises portfolio companies Novasenta, Generian, and Cerevance. He is also a member of the executive committee for the UPMC Genome Center.

Prior to UPMC Enterprises, Matthias spent nine years in management consulting at L.E.K. Consulting in its life sciences practice in Boston and London leading teams on over 70 strategic assignments for clients in the U.S., Europe, and Japan. Matthias completed his PhD in the Clinical Pharmacology Unit of the University of Cambridge (UK), working on early-stage discovery of G-protein-coupled receptor targets for hypertension, heart disease, and metabolic syndrome.

Matthias graduated from Justus Liebig University in Giessen (GER) with a doctorate in clinical veterinary medicine.